183 related articles for article (PubMed ID: 38110372)
1. Proteomics-driven noninvasive screening of circulating serum protein panels for the early diagnosis of hepatocellular carcinoma.
Xing X; Cai L; Ouyang J; Wang F; Li Z; Liu M; Wang Y; Zhou Y; Hu E; Huang C; Wu L; Liu J; Liu X
Nat Commun; 2023 Dec; 14(1):8392. PubMed ID: 38110372
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive evaluation of microRNA as a biomarker for the diagnosis of hepatocellular carcinoma.
Malik J; Klammer M; Rolny V; Chan HL; Piratvisuth T; Tanwandee T; Thongsawat S; Sukeepaisarnjaroen W; Esteban JI; Bes M; Köhler B; Swiatek-de Lange M
World J Gastroenterol; 2022 Aug; 28(29):3917-3933. PubMed ID: 36157551
[TBL] [Abstract][Full Text] [Related]
3. Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker.
Chen L; Ho DW; Lee NP; Sun S; Lam B; Wong KF; Yi X; Lau GK; Ng EW; Poon TC; Lai PB; Cai Z; Peng J; Leng X; Poon RT; Luk JM
Ann Surg Oncol; 2010 Sep; 17(9):2518-25. PubMed ID: 20354800
[TBL] [Abstract][Full Text] [Related]
4. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
[TBL] [Abstract][Full Text] [Related]
6. A Novel Online Calculator Based on Serum Biomarkers to Detect Hepatocellular Carcinoma among Patients with Hepatitis B.
Yang T; Xing H; Wang G; Wang N; Liu M; Yan C; Li H; Wei L; Li S; Fan Z; Shi M; Chen W; Cai S; Pawlik TM; Soh A; Beshiri A; Lau WY; Wu M; Zheng Y; Shen F
Clin Chem; 2019 Dec; 65(12):1543-1553. PubMed ID: 31672853
[TBL] [Abstract][Full Text] [Related]
7. Proteomic Analysis Identifies GSN as a Noninvasive Circulating Serum Biomarker for Predicting Early Recurrence of Hepatocellular Carcinoma.
Hu E; Yang T; Cai L; Ouyang J; Wang F; Li Z; Wang Y; Xing X; Liu X
J Proteome Res; 2024 Mar; 23(3):1062-1074. PubMed ID: 38373391
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
[TBL] [Abstract][Full Text] [Related]
9. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
Feng H; Li B; Li Z; Wei Q; Ren L
BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
[TBL] [Abstract][Full Text] [Related]
10. Liver Cancer-Specific Serine Protease Inhibitor Kazal Is a Potentially Novel Biomarker for the Early Detection of Hepatocellular Carcinoma.
Lu F; Shah PA; Rao A; Gifford-Hollingsworth C; Chen A; Trey G; Soryal M; Talat A; Aslam A; Nasir B; Choudhry S; Ishtiaq R; Sanoff H; Conteh LF; Noonan A; Hu KQ; Schmidt C; Fu M; Civan J; Xiao G; Lau DT; Lu X
Clin Transl Gastroenterol; 2020 Dec; 11(12):e00271. PubMed ID: 33512798
[TBL] [Abstract][Full Text] [Related]
11. Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early hepatocellular carcinoma in patients with cirrhosis.
Guo Y; Zhao J; Bi J; Wu Q; Wang X; Lai Q
J Hematol Oncol; 2012 Jul; 5():37. PubMed ID: 22760167
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: a nested case-control study in Chinese patients.
Yu R; Xiang X; Tan Z; Zhou Y; Wang H; Deng G
Sci Rep; 2016 Oct; 6():35050. PubMed ID: 27731353
[TBL] [Abstract][Full Text] [Related]
13. The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients.
Xu F; Zhang L; He W; Song D; Ji X; Shao J
Dis Markers; 2021; 2021():8868370. PubMed ID: 33628341
[TBL] [Abstract][Full Text] [Related]
14. Serum miR-224 as a biomarker for detection of hepatocellular carcinoma at early stage.
Lin L; Lu B; Yu J; Liu W; Zhou A
Clin Res Hepatol Gastroenterol; 2016 Sep; 40(4):397-404. PubMed ID: 26724963
[TBL] [Abstract][Full Text] [Related]
15. A Large-scale, multicenter serum metabolite biomarker identification study for the early detection of hepatocellular carcinoma.
Luo P; Yin P; Hua R; Tan Y; Li Z; Qiu G; Yin Z; Xie X; Wang X; Chen W; Zhou L; Wang X; Li Y; Chen H; Gao L; Lu X; Wu T; Wang H; Niu J; Xu G
Hepatology; 2018 Feb; 67(2):662-675. PubMed ID: 28960374
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of AFP, AFP-L3, and PIVKA-II, and their combinations in diagnosing hepatocellular carcinoma.
Park SJ; Jang JY; Jeong SW; Cho YK; Lee SH; Kim SG; Cha SW; Kim YS; Cho YD; Kim HS; Kim BS; Park S; Bang HI
Medicine (Baltimore); 2017 Mar; 96(11):e5811. PubMed ID: 28296720
[TBL] [Abstract][Full Text] [Related]
17. Optimisation of quantitative miRNA panels to consolidate the diagnostic surveillance of HBV-related hepatocellular carcinoma.
Tat Trung N; Duong DC; Tong HV; Hien TTT; Hoan PQ; Bang MH; Binh MT; Ky TD; Tung NL; Thinh NT; Sang VV; Thao LTP; Bock CT; Velavan TP; Meyer CG; Song LH; Toan NL
PLoS One; 2018; 13(4):e0196081. PubMed ID: 29672637
[TBL] [Abstract][Full Text] [Related]
18. Multimarker Panels for Detection of Early Stage Hepatocellular Carcinoma: A Prospective, Multicenter, Case-Control Study.
Piratvisuth T; Tanwandee T; Thongsawat S; Sukeepaisarnjaroen W; Esteban JI; Bes M; Köhler B; He Y; Swiatek-de Lange M; Morgenstern D; Chan HL
Hepatol Commun; 2022 Apr; 6(4):679-691. PubMed ID: 34796691
[TBL] [Abstract][Full Text] [Related]
19. Alpha-fetoprotein, protein induced by vitamin K absence or antagonist-II, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein alone and in combination for early detection of hepatocellular carcinoma from nonalcoholic fatty liver disease: A multicenter analysis.
Guan MC; Ouyang W; Liu SY; Sun LY; Chen WY; Tong XM; Zhu H; Yang T
Hepatobiliary Pancreat Dis Int; 2022 Dec; 21(6):559-568. PubMed ID: 35643910
[TBL] [Abstract][Full Text] [Related]
20. Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients.
Lim TS; Kim DY; Han KH; Kim HS; Shin SH; Jung KS; Kim BK; Kim SU; Park JY; Ahn SH
Scand J Gastroenterol; 2016 Mar; 51(3):344-53. PubMed ID: 26340708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
